Status:

RECRUITING

Effectiveness and Safety of Adjuvant Software Based on Virtual Reality for Post-thoracoscopic Surgery Pain

Lead Sponsor:

Guangdong Provincial People's Hospital

Collaborating Sponsors:

Guang Dong Liang Zi Health Consulting Co., Ltd, Guang Dong, China.

Tianjin Medical University General Hospital

Conditions:

Acute Postoperative Pain

Video-assisted Thoracic Surgery

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A randomized controlled, prospective, multicenter, open label, superiority trial aims to evaluate the effectiveness and safety of adjuvant software based on virtual reality for post-thoracoscopic surg...

Detailed Description

215 eligible patients will be enrolled. All enrolled patients will have an NRS score at 24 hours postoperatively, and those with a score greater than or equal to 4 will be randomly assigned to the tes...

Eligibility Criteria

Inclusion

  • Age greater than or equal to 18 years.
  • Patients within 1 day after thoracoscopic surgery.
  • Junior high school degree or above, Mandarin communication is unimpeded, with certain Internet knowledge and mobile phone reading and writing skills.
  • The score of the numeric grading scale (NRS) at 24 hours postoperatively ≥ 4 points.
  • Patients who are able to understand the purpose of the study, voluntarily participate in and sign the informed consent form, and are willing to complete the follow-up as required by the protocol.

Exclusion

  • Patients with severe cognitive impairment.
  • Patients with a previous diagnosis of epilepsy, dementia, migraine, or other neurological disease that may result in the inability to use postoperative analgesic adjuvant therapy software or that may have adverse effects.
  • Patients who are unable to understand or speak Mandarin.
  • Patients who have visual abnormalities, severe hearing impairment, or motion sickness, etc., and are unable to view VR.
  • Patients with trauma to the eyes, face, or neck that prevents the comfortable use of the VR device.
  • Patients with severe heart, liver, kidney, hematologic, digestive, nervous system diseases and malnutrition.
  • Patients who have previously used virtual reality software for pain that has not responded to treatment.
  • Patients with a history of severe alcohol abuse, long-term heavy drinking, and symptoms of alcohol dependence.
  • Patients who have participated in any analgesic interventional study within the past 1 week.
  • Females who are pregnant or plan to become pregnant during the study.
  • The patient or their immediate family member works for a digital health or pharmaceutical company for acute or chronic pain treatment.
  • Patients who are unable to use electronic devices such as smartphones.
  • Other conditions that the investigator considers inappropriate for participation in a clinical trial.

Key Trial Info

Start Date :

April 22 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 24 2025

Estimated Enrollment :

215 Patients enrolled

Trial Details

Trial ID

NCT06574451

Start Date

April 22 2023

End Date

April 24 2025

Last Update

August 28 2024

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences

Guangzhou, Guangdong, China, 510080

2

Maoming People's Hospital

Maoming, Guangdong, China

3

Ruijing Hospital, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China

4

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China